Table 2.
Multivariable Survival Analyses of Subtype Groupings in Patients Treated With Surgery Alone (observation arm; n = 293)
| Subtype | OS |
DFS |
SDFS |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Deaths | HR | 95% CI | P | No. of Events | HR | 95% CI | P | No. of Events | HR | 95% CI | P | |
| LEP | 6 of 13 | 1.0 | 6 of 13 | 1.0 | 6 of 13 | 1.0 | ||||||
| ACN/PAP | 50 of 116 | 0.70 | 0.29 to 1.69 | 59 of 116 | 0.87 | 0.37 to 2.07 | 53 of 116 | 0.82 | 0.34 to 1.95 | |||
| MIP/SOL | 89 of 164 | 0.96 | 0.40 to 2.30 | 109 of 164 | 1.32 | 0.56 to 3.13 | 101 of 164 | 1.29 | 0.55 to 3.07 | |||
| Overall test* | .22 | .05 | .04 | |||||||||
| Test of heterogeneity across trials† | .70‡ | .86‡ | .96‡ | |||||||||
| .76§ | .96§ | .97§ | ||||||||||
| .95‖ | .98‖ | 1.00‖ | ||||||||||
NOTE. Similar results were observed when using TNM stage instead of T and N of TNM in multivariable Cox regression model (data not shown).
Abbreviations: ACN, acinar; DFS, disease-free survival; HR, hazard ratio; LEP, lepidic; MIP, micropapillary; OS, overall survival; PAP, papillary; SDFS, specific disease-free survival; SOL, solid.
Test of global association.
ANITA (Adjuvant Navelbine International Trialist Association) trial was excluded to test heterogeneity across trials, because there was no patient with LEP subtype in this trial.
Test evaluating homogeneity of prognostic effect across trials in ACN/PAP group (v LEP group).
Test evaluating homogeneity of prognostic effect across trials in MIP/SOL group (v LEP group).
Test evaluating joint hypotheses of ‡ and §.